Previous close | 0.00 |
Open | 17.53 |
Bid | 15.68 x 47300 |
Ask | 18.04 x 34100 |
Day's range | 17.53 - 17.53 |
52-week range | 12.48 - 19.84 |
Volume | |
Avg. volume | 1,895 |
Market cap | 26.488B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 38.78 |
EPS (TTM) | 0.46 |
Earnings date | 08 Aug 2024 |
Forward dividend & yield | 0.17 (0.93%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
COLORADO SPRINGS, Colo. & ALISO VIEJO, Calif., July 23, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms. The CLEVER study was a multicenter, prospective study evaluating the WEB 17 system in ruptured and unruptured aneurysms to understand the s
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.